Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Dr. Stanley Schwartz relates his overwhelmingly positive experience treating patients with newer drug therapies such as GLP-1 agonists and SGLT-2 inhibitors. He explains that he will sometimes put patients, on the very first day of their visit, on these medications when their A1c’s are very high and, one month later, their blood sugars have dropped dramatically, they’ve lost weight, and they feel great…
Dr. Stanley Schwartz relates his overwhelmingly positive experience treating patients with newer drug therapies such as GLP-1 agonists and SGLT-2 inhibitors. He explains that he will sometimes put patients, on the very first day of their visit, on these medications when their A1c’s are very high and, one month later, their blood sugars have dropped dramatically, they’ve lost weight, and they feel great.
More videos in this series with Dr. Schwartz
- Stanley Schwartz, MD, FACP, FACE: Introduction, ADA 2014
- A New Way of Classifying Diabetes – The Beta-Cell Centric Approach
- Picking the Right Drugs for the Right Patients
- Why Sulfonylureas Should No Longer Be Used
- How Do You Determine Beta Cell Function?
- Prescribing Medications for Prediabetes
- Next Steps for a “Beta-Cell-Centric” Approach
Stanley Schwartz, MD, has been awarded the honor of being a TOP DOC by Philadelphia Magazine many times over the years, including 2009, 2010 and 2011 for the treatment of diabetes and metabolic syndrome. For over 30 years, Dr. Schwartz was an Associate Professor at the University of Pennsylvania, most recently directing the Diabetes Program at the Philadelphia Heart Institute. Dr. Stanley Schwartz is a new Affiliate of the Main Line Health System, and an Emeritus Associate Professor of Medicine at the University of Pennsylvania, currently in a private practice in Ardmore, Pa. Dr. Schwartz received his MD in 1973 from the University of Chicago in Chicago, Illinois. He then completed his residency at the University of Pennsylvania, followed by a fellowship in endocrinology and metabolism at the University of Chicago.
See more SGLT-2 Resources